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A high affinity (1-2 nM) radioiodinated, photoaffinity probe for the dopamine transporter, I-(2-[bis-(4fluorophenyl)- 
methoxylethyl)-4-(2-[4-azido-3-~*sI]iodophenyl]ethyl)piperazine (pZ51]FAPP) has been synthesized. Upon photolysis, 
Pz51]FAPP incorporates into a striatal polypeptide of apparent M, 62000 as visualized by autoradiography following 
sodium dodecyl sulfate-PAGE. Photoincorporation of rZ51]FAPP into the M, 62000 polypeptide was stereoselectively 
inhibited by various dopamine uptake agents with a potency order typical of the dopamine transporter. The glycoprotein 
nature of the apparent M, 62000 polypeptide was assessed following specific exo- and endoglycosidase treatment. The 
dopamine transporter appears to be associated with complex-type oligosaccharides as indexed by its susceptibility to 
neuraminidase but not a-mannosidase digestion. Complete N-linked deglycosylation of the neuronal dopamine trans- 
porter with the endoglycosidase, glycopeptidase-F, increased the electrophoretic mobility of the 62 kDa polypeptide to 
apparent M, 48000. [iZ51]FAPP should prove to be a useful probe for the molecular characterization of the dopamine 
uptake site in various tissues and under certain pathophysiological states. 
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1. INTRODUCTION 
[3H]GBR-12935 (l-[2-diphenylmethoxy]ethyl)-C 
(3-phenylpropyl)piperazine [1,2] and [3H]GBR- 
12783 (l-[2-diphenylmethoxy]ethyl)-4-(3-phenyl-2- 
propenyl)piperazine) [3] have been widely used as 
selective and high affinity radiolabeled probes for 
the dopamine transporter in both rat and human 
brain [4-81. These radioligands represent 
derivatives of a series of aryl-dialkylpiperazines 
with potent and selective dopamine uptake in- 
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hibiting properties [9,10]. The binding of 
[3H]GBR-12935 to rat and human striatal mem- 
branes has been convincingly demonstrated, on 
both pharmacological and biochemical grounds to 
be related to the dopamine uptake site (see above 
refs). 
In order to examine some of the molecular 
events associated with the dopamine uptake pro- 
cess, it would be helpful to be able to covalently 
label the dopamine transporter by means of a 
radioactive photoaffinity probe. Although both 
dopamine Dr and D2 receptors can now be so iden- 
tified (see [11,12]) the elucidation of the structure 
of the dopamine transporter has been limited by 
the lack of a suitable radioiodinated photoaffinity 
label. In this paper, we document he synthesis and 
characterization of a high affinity, radioiodinated 
arylazide derivative of the dopamine uptake 
blocker GBR-12909, [“‘I]FAPP. This ligand, 
upon photolysis, incorporates with high efficiency 
into a polypeptide of apparent Mr 62CKKl represen- 
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ting the neuronal ligand binding subunit of the 
dopamine transporter in both canine and human 
striatal membranes. Moreover, as a first step 
towards understanding the molecular structure of 
the neuronal dopamine transporter, we assessed 
the glycoprotein nature of [‘251]FAPP-labeled 
membranes following digestion with specific exo- 
and endoglycosidases. 
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2. MATERIALS AND METHODS 1 
3 
[3H]GBR-12935 (30 Ci/mmol) was obtained from New 
England Nuclear. Digitonin was obtained from Wako Chemical 
Co. and Sephadex G-50 was from Pharmacia. GBR-12909 was 
purchased from Research Biochemical Inc. and GBR-12937 was 
kindly provided by Dr P. Andersen of Novo Industries A/S. 
(+)- and (-)-diclofensine were obtained from Roche, and 
mazindol, nomifensine and methylphenidate were generously 
donated by the following pharmaceutical firms: Sandoz 
Research Inst., Hoechst Pharmaceutical, Ciba-Geigy Corp., 
and Sterling-Winthop. Dopamine, pemoline, cocaine, 
noradrenaline, neuraminidase (type x from Clostridium perfr- 
ingens), a-mannosidase (Jack-bean), PMSF, benzamidine, 
leupeptin, pepstatin A and soybean trypsin inhibitor were from 
Sigma Chemicals. Glycopeptidase-F (peptide-N’-[N-acetyl-fl- 
glucosaminyllasparagine-amidase) from Flavobacterium men- 
ingosepticum was obtained from Boehringer-Mannheim. Elec- 
trophoresis reagents were from Calbiochem Inc. and prestained 
molecular weight standards were from Amersham. All other 
drugs and reagents were obtained from sources previously 
described [12]. Canine brains were purchased from Pel Freez 
Biol. (Arkansas). 
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Fig.1. Structure and synthetic route of [“‘IJFAPP. 
2.1. Synthesis of [lzsI]FAPP 
The complete synthesis and chemical characterization of 
IFAPP will be described in a forthcoming publication 
(Schwartz, E. et al., in preparation). The structure and general 
synthetic route of [“‘I]FAPP are depicted in fig. 1. Briefly, the 
synthesis of the non-radioactive photoaffinity label 7 began 
with the condensation of 4,4’-difluorobenzhydrol, 1 
(19.6 mmol), and 2-chloroethanol (1.5 e.g.) in benzene (20 ml, 
reflux, 30 min) under acid catalysis (0.1 ml cont. HzS04) to 
provide the ether 2 in ca. 90% yield (Rr = 0.39, 10% 
EtOAc/hexane). The chloride 2 (10 mmol) was treated with an 
excess of piperazine and anhydrous KzCO3 (ca. 4.5 eq. of each) 
to afford the mono-alkylated piperazine 3 (ca. 90% yield; Rr = 
0.10, 85% EtOAc/lO% hexane/5% EtlN). Subsequent alkyla- 
tion of 3 (1.33 mmol) with 4-nitrophenethyl bromide (1.2 eq.) 
in acetonitrile (8 ml, reflux, 5 h) in the presence of an excess of 
anhydrous K2CO3 provided piperazine 4 in 55% yield after 
flash chromatography (RI = 0.45, 85% EtOAc/lO% hex- 
ane/5% Et3N). 
HOAc afforded the iodoaniline 6 in 64% yield after neutraliza- 
tion of the reaction mixture (aq. NaHCO& extraction with 
EtzO, and flash chromatography (Rf = 0.29, 95% EtOAc/S% 
Et3N). Diazotization of the amine 6 (0.16 mmol, 1.5 eq. 
NaNOz in 7 ml 3 M aq. HOAc and 2 ml MeOH, O’C) followed 
by direct reaction with NaNs (1.5 eq.) provided the iodoazide 7 
in 80% yield after flash chromatography (Rf = 0.53, 85% 
EtOAc/lO% hexane/5% EtsN). 
As is to be described elsewhere (Schwartz et al., in prepara- 
tion), [‘2SI]FAPP (2200 Ci/mmol) was custom-prepared and 
purified by New England Nuclear. 
2.2. Membrane preparation 
Striata dissected from oartiallv thawed canine brains were 
prepared as previously described [12]. For some experiments, 
membranes were prepared in 25 mM Tris-HCl buffer alone (pH 
7.4 at 4°C) without the addition of protease inhibitors. 
2.3. Photoaffinity labeling 
Reduction of the nitro group of 4 was accomplished using 5% Membranes (-200 pg) were routinely incubated (in the dark) 
palladium on activated carbon in ethanol under 1 atm. of HZ. with 1 nM [“sI]FAPP at a dopamine uptake site concentration 
Filtration of the reaction mixture through, Celite followed by of -800 pM in a total volume of 1 ml for 90 min at 4°C in the 
solvent removal gave the aniline 5 in 95-100% yield (Rr = 0.30, presence or absence of dopaminergic agents as indicated. After 
95% EtOAc/S% EtSN). Slow addition of iodine monochloride incubation, samples were centrifuged (Eppendorf no.5415) at 
(1.3 eq. in 2 ml HOAc) to a solution of 5 (0.44 mmol) in 2 ml 14000 rpm for 2 min. Membrane pellets were resuspended in 
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1 ml of 25 mM Tris-HCl buffer containing 100 mM NaCl and 
protease inhibitors (where indicated), and irradiated for 35 s as 
previously described [12]. [1251]FAPP-labeled membranes were 
sedimented at 14000 rpm for 2 min and used as described 
below. 
2.4. Exoglycosidase treatments 
For neuraminidase treatment, [‘2sI]FAPP-labeled mem- 
branes were washed twice in 1 ml of 100 mM sodium acetate 
buffer, pH 5 at 22°C. Membranes were resuspended in the same 
buffer at 0.5-1.0 mg/ml, to which neuraminidase was added at 
a concentration of 2 U/ml and incubated for 15 min at 37°C. 
After incubation, membranes were washed and solubilized in 
SDS-buffer as described below. For a-mannosidase treatment, 
[‘251]FAPP-labeled membranes were washed twice with ,l ml of 
50 mM sodium citrate buffer (pH 4.5 at 22°C) containing 
100 /IM PMSF and 3 yg/ml pepstatin A and resuspended in the 
same buffer to which was added up to 6 U/ml of CY- 
mannosidase and incubated overnight at 22°C. Pelleted mem- 
branes were then processed for SDS-PAGE as described below. 
2.5. Endoglycosidase treatments 
[‘2sI]FAPP-photolabeled receptors (as described above) were 
washed twice in 1 ml of 200 mM sodium phosphate buffer con- 
taining 10 mM EDTA, pH 8.0, at 22°C. Pellets were resuspend- 
ed in the same buffer to which was added 0.5% SDS and 
100 mM fl-mercaptoethanol and incubated for 1 h at 22°C in a 
Mr 
69 - 
46 - 
10/~M 
Mr 
total volume of 60 ~1. Nonidet P-40 (1.25% final concentration) 
was then added to the samples followed by the addition of 
PNGase-F (at a concentration of 50 U/ml) and incubated for 
6-22 h at 37°C in a total volume of 90~1. After incubation, 
samples were pelleted and membranes solubilized in SDS- 
PAGE sample buffer, as described below. 
2.6. SDS-PAGE and autoradiography 
Electrophoresis and autoradiography were performed as 
previously described [ 121. 
3. RESULTS AND DISCUSSION 
The product described here yields a novel 
analogue of the potent dopamine uptake blocker, 
GBR-12909. The compound, IFAPP, possesses an 
azido-phenyl substituent hat renders it as a potent 
photoaffinity probe for the dopamine transporter. 
The capacity of IFAPP to interact with dopamine 
uptake sites was assessed in competition binding 
experiments with [3H]GBR-12935. IFAPP 
displayed a high affinity for digitonin-solubilized 
[3H]GBR-12935 binding sites with an estimated Ki 
46 - 
30 - 
Fig.2. Pharmacological specificity of [‘251]FAPP-labeled membranes from canine striatum. Samples were photolyzed in the absence 
or presence of the indicated concentrations of dopaminergic uptake agents and subjected to SDS-PAGE and autoradiography as 
described in section 2. A.4, of known molecular weight standards are shown x 10e3. These results are representative of 3 independent 
experiments. 
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value of -3 nM. Thus, the introduction of both 
iodo and azido substituents did not interfere with 
the capacity of IFAPP to interact with the 
dopamine transporter compared to the parent 
compound, GBR-12909 (Ki - 3 nM). 
The major objective of this work was to develop 
an arylazide derivative of GBR-12909 that can 
upon photolysis incorporate into the ligand bin- 
ding subunit of the dopamine transporter. Fig.2 il- 
lustrates the results obtained when canine striatal 
membranes were incubated with [i2’I]FAPP, sub- 
jected to photolysis, SDS-PAGE and 
autoradiography. A broad band was labeled at ap- 
parent M, 62000. The specificity of labeling was 
shown by virtue of the fact that GBR-12909 block- 
ed the photoincorporation of [i2’I]FAPP into the 
M, 62000 polypeptide. Three non-specifically 
labeled bands at apparent MI 90000, 50000 and 
32000 were also seen. The pharmacological 
specificity of [i2?]FAPP photoincorporation was 
further assessed by examining the capacity of 
various dopamine uptake blockers and substrates 
to block labeling of the h4* 62000 polypeptide. As 
seen in fig.2 the photo-dependent labeling of the 
62 kDa polypeptide was stereoselectively an- 
tagonized by diclofensine and cocaine and by 
dopamine uptake inhibitors and substrates uch as 
mazindol, methylphenidate, nomifensine and 
dopamine, but not by the serotonin uptake in- 
hibitor, imipramine or noradrenaline. These data 
strongly suggest hat the 62 kDa labeled polypep- 
tide is the ligand binding subunit of the dopamine 
transporter. Similarly, a 62 kDa specifically label- 
ed polypeptide was identified in membranes from 
human putamen (data not shown). 
In order to assess whether the [1251]FAPP- 
labeled polypeptide of Mr 62000 is a derivative of 
a larger molecular weight protein or contains 
disulfide linkages, we examined the electrophoretic 
mobility of [‘251]FAPP-labeled membranes 
photolabeled in either the absence or presence of 
multiple protease inhibitors (see [12]) or treated 
with thiol-reducing reagents prior to SDS-PAGE. 
As shown in fig.3, neither of these conditions 
altered the electrophoretic mobility of the 
dopamine transporter. These data suggest hat the 
M, 62000 labeled polypeptide is probably not a 
proteolytic derivative of a larger molecular weight 
species and is not linked by intramolecular 
disulfide bridges. 
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Fig.3. Effect of protease inhibitors and reducing agents on the 
electrophoretic mobility of [1Z51]FAPP-labeled membranes. 
Samples were photolyzed in the absence or presence of multiple 
protease inhibitors (20 mM EDTA, 15 pg/ml benzamidine, 
5 pg/ml leupeptin and soybean trypsin inhibitor, 1 mM PMSF) 
and solubihzed in sample buffer in the absence or presence of 
10% ,8-mercaptoethanol @-ME). M, of known molecular 
weight standards are shown x 10m3. 
As illustrated in fig.4, the M, 62000 labeled 
polypeptide appears to be associated with glycan 
chains containing sialic acid/n-acetylglucosamine 
residues since neuraminidase but not LY- 
mannosidase treatment altered the electrophoretic 
mobility of the dopamine transporter to apparent 
Mr 56000. Sequential treatment with both en- 
zymes, irrespective of order, did not further in- 
crease the mobility of the 62 kDa polypeptide. 
These data are consistent with the observations 
that the dopamine uptake site is a complex type 
glycoprotein as indexed by the interaction of 
solubilized [3H]GBR-12935 binding sites with 
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Fig.4. Exoglycosidase treatment of [‘251]FAPP-labeled 
dopamine uptake sites. Membranes were labeled with 
[‘251]FAPP, washed with the appropriate buffer and incubated 
with buffer alone or with the indicated concentrations of 
neuraminidase or a-mannoside as described in section 2. 
Included in this gel are lanes demonstrating non-specific 
labeling as defined by 1 pM GBR-12909, and sequential 
neuraminidine and a-mannosidase treatments. M, of protein 
standards are shown x 10m3. 
various lectins [ 13,141 and the role of sialic acid 
residues in the dopamine uptake process [ 151. 
The peptide backbone of the dopamine 
transporter was assessed following complete N- 
linked deglycosylation with PNGase-F [16]. As 
seen in fig.5, PNGase-F treatment of [‘*‘I]FAPP- 
labeled membranes for either 6 or 22 h increased 
the electrophoretic mobility of the 62 kDa labeled 
polypeptide to apparent Mr 48000. In addition, a 
minor (-10%) polypeptide of apparent M, 44000 
was also seen. At present it is unknown whether 
46 - 
30 - 
ABCD 
PNGase-F - + + + 
UU 
22h 6h 
Fig.5. Effect of PNGase-F treatment on the electrophoretic 
mobility of the dopamine transporter. [‘251]FAPP-labeled 
membranes were prepared for enzyme treatment as described. 
Aliquots were incubated with buffer alone (A) or with 50 U/ml 
PNGase-F for 22 h (lane B) at 37°C. Lane C, same as B except 
photolabeling in the presence of 1 PM GBR-12909; lane D same 
as B except for a 6 h incubation. 
this fragment represents a proteolytic degradation 
product of the M, 48000 protein or is evidence for 
multiple N-linked glycosylation sites on the 
transporter. Moreover, it is difficult to ascertain 
whether the 48 kDa polypeptide represents just the 
ligand binding subunit alone or the entire 
dopamine transport protein. Final assessment will 
have to await the purification of dopamine uptake 
site and its functional reconstitution and/or the 
isolation of cDNA clones encoding its synthesis. 
In any event, the introduction of this specific, 
high affinity, radioiodinated, photoaffinity probe 
for the dopamine transporter should prove to be of 
223 
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value for the subsequent molecular characteriza- 
tion and purification of this important membrane 
protein. 
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